Future diagnosis and treatment of colorectal cancer from the view of precision medicine.
- Author:
Hongwei YAO
1
;
Chang SHU
;
Songnian HU
2
;
Yinhua LIU
3
Author Information
1. Department of General Surgery, Peking University Third Hospital, Beijing 100191, China. rendl111@163.com.
2. Beijing Institute of Genomics, Chinese Academy of Science, Beijing 100101, China. husn@big.ac.cn.
3. Department of General Surgery, Peking University First Hospital, Beijing 100034, China. rendl111@163.com.
- Publication Type:Editorial
- MeSH:
China;
Colorectal Neoplasms;
Humans;
Mutation;
Precision Medicine;
Proteomics;
Recurrence
- From:
Chinese Journal of Gastrointestinal Surgery
2016;19(1):7-12
- CountryChina
- Language:Chinese
-
Abstract:
China has entered a period of high incidence of colorectal cancer. The year of 2015 is the start of precision medicine. Colorectal cancer "precision medicine" is based on the analysis of the cancer genome sequencing and information analysis, interprets the mechanism of the occurrence, development, invasion, metastasis and recurrence of colorectal cancer, and helps to implement targeted individual treatment. The experts of the world's Colorectal Cancer Subtyping Consortium, integrated the past genetic testing based on the classification of colorectal cancer subtypes, refered to the indices of gene mutation, copy number, methylation, microRNA and proteomics, and coalesce the types of colorectal cancer into four consensus molecular subtypes(CMSs) with distinguishing features. CMSs may be the most powerful classification system of colorectal cancer because of its clear biological interpretation, and is expected to provide a reference basis for the establishment of clinical precision treatment system.
